HCPCS J0696 is officially defined as "Injection, ceftriaxone sodium, per 250 mg." HCPCS J0696 is referenced in 5 tracked payer policy changes from Anthem BCBS and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J0696 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
California Medicaid (Medi-Cal) now requires National Drug Codes (NDCs) in 11-digit 5-4-2 format for all outpatient claims that include drug-related services billed with HCPCS drug codes. NDCs must match the actual drug container administered, include proper unit of measure (UOM) codes, and be formatted without hyphens or spaces. Missing, incorrect, or misformatted NDC information will delay claim reimbursement.
New York Medicaid now requires National Drug Codes (NDCs) in 11-digit 5-4-2 format for all outpatient claims with drug-related services billed using HCPCS codes. NDCs must match the actual product administered, include proper unit of measure (ML, UN, GR, F2), and be submitted without hyphens or spaces. Incorrect or missing NDC information will delay reimbursement.
Virginia Medicaid (Anthem HealthKeepers) now requires National Drug Codes (NDCs) in 11-digit 5-4-2 format on all outpatient claims that include drug-related services billed with HCPCS drug codes. NDCs must match the actual product administered, be properly formatted with leading zeros, and include correct units of measure (UOM) to avoid claim denials and processing delays.
Anthem Blue Cross (California) is enforcing stricter National Drug Code (NDC) validation requirements for all pharmacy claims submitted to them, effective April 1, 2026. Providers must submit 11-digit NDCs in proper format with correct units of measure (UOM) and quantities on all drug-related professional and outpatient claims. Missing, incorrectly formatted, or mismatched NDCs will delay reimbursement.
Treatment of Lyme disease consists of oral antibiotics except for neuroborreliosis, Lyme carditis and Lyme arthritis. A 2- to 4-week course of IV antibiotics may be considered medically necessary for neuroborreliosis with objective neurologic complications of documented Lyme disease, and a single 2- to 4-week IV course may be considered for Lyme carditis or for the small subset of well-documented Lyme arthritis that is severe enough to need the rapid response of IV antibiotics. IV antibiotic therapy is considered investigational for conditions such as chronic fatigue syndrome or fibromyalgia without objective evidence of Lyme disease, post-Lyme syndrome, and repeat or prolonged courses longer than 4 weeks.
Watch J0696
Get one email when a payer policy names J0696, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J0696
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J0696 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.